Found: 16
Select item for more details and to access through your institution.
Palonosetron in the management of chemotherapyinduced nausea and vomiting in patients receiving multiple-day chemotherapy.
- Published in:
- Cancer Management & Research, 2014, v. 6, p. 329, doi. 10.2147/CMAR.S68102
- By:
- Publication type:
- Article
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.
- Published in:
- Oncologist, 2018, v. 23, n. 8, p. 889, doi. 10.1634/theoncologist.2018-0149
- By:
- Publication type:
- Article
Music Intervention: Nonpharmacologic method to reduce pain and anxiety in adult patients undergoing bone marrow procedures.
- Published in:
- Clinical Journal of Oncology Nursing, 2021, v. 25, n. 3, p. 314, doi. 10.1188/21.CJON.314-320
- By:
- Publication type:
- Article
A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Overall Survival of Newly Diagnosed Glioblastoma Patients Receiving Carmustine Wafers Followed by Radiation and Concurrent Temozolomide Plus Rotational Multiagent Chemotherapy.
- Published in:
- Cancer (0008543X), 2009, v. 115, n. 15, p. 3501, doi. 10.1002/cncr.24398
- By:
- Publication type:
- Article
BOOK REVIEWS.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1990, v. 82, n. 5, p. 425
- By:
- Publication type:
- Article
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
- Published in:
- Neuro-Oncology, 2004, v. 6, n. 2, p. 145, doi. 10.1215/S1152851703000498
- By:
- Publication type:
- Article
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
- Published in:
- Neuro-Oncology, 2004, v. 6, n. 2, p. 134, doi. 10.1215/S1152851703000413
- By:
- Publication type:
- Article
MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 6, p. 1, doi. 10.1007/s00520-024-08543-x
- By:
- Publication type:
- Article
2023 MASCC/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 1, p. 1, doi. 10.1007/s00520-023-08225-0
- By:
- Publication type:
- Article
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide"
- Published in:
- 2020
- By:
- Publication type:
- Letter
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
- Published in:
- 2016
- By:
- Publication type:
- journal article
The Impact of Independent Chemotherapy Prescribing by Advanced Practice Providers on Patient Safety and Clinician Satisfaction.
- Published in:
- Clinical Journal of Oncology Nursing, 2024, v. 28, n. 4, p. 397, doi. 10.1188/24.CJON.397-405
- By:
- Publication type:
- Article
The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.
- Published in:
- 1990
- By:
- Publication type:
- journal article